SEC Form 4 · accession 0001724310-26-000007
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ryan J. Watts
Officer — President and CEO · Director
Period of report
Aug 12, 2026
Accepted (ET)
Aug 14, 2026 · 4:48 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001714899
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 12, 2026 | G | 32,220 | $0.00 | D | 2,120,384 | I | See footnote |
| Common StockF3 | holding | — | — | — | 296,833 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects an in-kind charitable contribution of 32,220 shares of DNLI to a donor advised fund.
- F2The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
- F3Includes 184,915 unvested RSUs.